Johnson & Johnson Q3 2026 Earnings Recap

Johnson & Johnson shares fell 3.7% after earnings, despite 6% operational sales growth, as the call offered no clear evidence of a guidance cut or specific shortfall to explain the reaction. Management said the company remained on track to meet its 2026 outlook, but that reassurance may not have been enough to offset investor concerns not detailed in the available transcript.

Key Takeaways

• Q3 operational sales grew 6%, which management said was ahead of analyst consensus; quarterly sales exceeded $25 billion.
• Innovative Medicine grew 7.9%. Oncology sales rose approximately 17%, while RYBREVANT sales increased 64%.
• Tremfya sales grew 68%; CAPLYTA reached $1 billion in year-to-date sales, and SPRAVATO grew 36%.
• Management said J&J was on track to meet 2026 guidance and exceed $100 billion in annual revenue for the first time.
• The supplied transcript ends during the MedTech discussion, so it does not provide the full segment results or CFO’s detailed guidance.